Tenvie Therapeutics raised $200 million to develop small molecules for treating neurological disorders.

Jan 08, 2025•11 months ago

Amount Raised

$200 Million

South San FranciscoTherapeuticsBiotechnologyHealth Care

Description

Tenvie Therapeutics secured $200 million in its debut financing round, making it the largest raise among the recent batch of biotech funding. This financing aims to support the development of their innovative treatments for neurological disorders.

Company Information

Company

Tenvie Therapeutics

Location

South San Francisco, California, United States

About

Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. The company’s most advanced programs target NLRP3 and SARM1, with additional programs in preclinical development.

Related People

3 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Tenvie Therapeutics raised $200 million to develop small molecules for treating neurological disorders.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information